Indivior Pharmaceuticals, Inc. (INDV) Q3 2024 Earnings
INDV·Reported October 24, 2024·Before market open
Indivior Pharmaceuticals, Inc. reported Q3 2024 revenue of $307.0M, beat analyst consensus of $260.4M by $46.6M. Diluted EPS came in at $0.54, beat the $0.31 consensus by $0.23.
Revenue
$307.0Mbeat by $46.6M
Consensus: $260.4MDiluted EPS
$0.54beat by $0.23
Consensus: $0.31
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q3 2024 Earnings FAQ
Common questions about Indivior Pharmaceuticals, Inc. 's Q3 2024 earnings report.
Indivior Pharmaceuticals, Inc. (INDV) reported Q3 2024 earnings on October 24, 2024 before market open.
Indivior Pharmaceuticals, Inc. reported revenue of $307.0M and diluted EPS of $0.54 for Q3 2024.
Revenue beat the consensus estimate of $260.4M by $46.6M. EPS beat the consensus estimate of $0.31 by $0.23.